In November 2023, the FDA added BPC-157 to its list of substances that cannot be used in compounding under the Federal Food, Drug, and Cosmetic Act, citing insufficient safety data for human use 3
We therefore studied whether BPC 157 could modulate the interaction between eNOS and Cav-1
Patients on Specific Medications: Certain medications, like proton pump inhibitors or metformin, can interfere with B12 absorption, making monitoring and supplementation necessary
If tolerated well and improvements continue, they may maintain or cautiously increase to 300400 mcg every other day or daily depending on individual response
Yes, of course
IGF-1 should be monitored at baseline, at 6 weeks, and at cycle end